TL;DR
This Phase 1b study investigated tilvestamab, an anti-AXL antibody, in patients with relapsed, platinum-resistant high-grade serous ovarian cancer (PROC). While tilvestamab was found to be generally well-tolerated and showed evidence of target engagement (downregulation of AXL and related pathways), it did not demonstrate significant anti-tumor responses in this patient population.
What Problem Does This Paper Address?
Epithelial ovarian cancer (EOC) is a highly lethal gynecologic malignancy, with high-grade serous ovarian cancer (HGSOC) being the most common subtype. While initial treatment often involves surgery and platinum-based chemotherapy, most patients eventually develop recurrent disease. Platinum-resistant ovarian cancer (PROC) is particularly challenging, as it signifies disease relapse within six months of completing platinum-based chemotherapy, leaving patients with limited effective treatment options. The AXL receptor tyrosine kinase is implicated in various aspects of cancer progression, including metastasis, immune evasion, and drug resistance, making it a potential therapeutic target. This study aimed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of tilvestamab, a novel anti-AXL antibody, in patients with PROC.
Methods
This was an open-label, multicenter, prospective, single-arm, dose-escalation Phase 1b study. Patients received tilvestamab intravenously every two weeks at three dose levels: 1 mg/kg, 3 mg/kg, and 5 mg/kg. The primary objectives were to assess safety, tolerability, and PK. Secondary objectives included immunogenicity, and exploratory objectives focused on overall response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and quality-of-life (QOL) measures. Pharmacodynamic (PD) assessments involved analyzing AXL expression, gene, and protein changes in tumor biopsies and blood samples.
Datasets
Not discussed in the paper.
Key Insights and Ideas
- AXL as a Target in Ovarian Cancer: The study reinforces the rationale for targeting AXL in ovarian cancer, given its overexpression in advanced disease and its role in promoting metastasis and resistance.
- Tilvestamab's Safety Profile: Tilvestamab demonstrated a generally favorable safety profile, with most adverse events being mild to moderate. Importantly, no grade 3 or higher treatment-related adverse events were observed.
- Evidence of Target Engagement: Pharmacodynamic analyses provided crucial insights, showing a reduction in AXL protein expression and downstream signaling pathways (like AKT and AMPK activation) in patients treated with tilvestamab. This suggests the drug is engaging its intended target.
- Reversal of EMT and Fibrosis Pathways: The study observed a potential reversal of epithelial-mesenchymal transition (EMT) and a reduction in pulmonary fibrosis-related gene signatures, hinting at tilvestamab's ability to modulate the tumor microenvironment.
- Lack of Clinical Efficacy: Despite target engagement, tilvestamab monotherapy did not lead to objective anti-tumor responses (CR or PR) in this PROC patient population. The best overall response observed was stable disease in 44% of patients at 6 weeks.
- AXL Expression and Response Correlation: Interestingly, AXL IHC-negative patients showed a higher rate of stable disease compared to AXL-positive patients, suggesting that AXL expression status by IHC might not be a reliable predictor of response to tilvestamab monotherapy in this context.
Key Results
- A total of 16 patients were enrolled.
- Tilvestamab was generally well-tolerated, with 94% of patients experiencing treatment-emergent adverse events (TEAEs), but only 62.5% experienced grade ≥3 TEAEs.
- Common TEAEs included fatigue (38%), anorexia (38%), and infections (31%).
- No objective responses (CR or PR) were observed.
- Stable disease (SD) at 6 weeks was achieved in 7 (44%) patients.
- Median progression-free survival (PFS) was 6 weeks.
- Pharmacokinetic analyses showed dose-proportional exposure and steady-state by the second dose, with minimal accumulation.
- Pharmacodynamic analyses indicated downregulation of AXL protein expression and modulation of related gene signatures.
Limitations and Future Work
The authors acknowledge several limitations. The study was a Phase 1b trial with a small sample size, which limits definitive conclusions about efficacy. The lack of objective responses in this patient population suggests that tilvestamab monotherapy may not be sufficient for PROC. Future work should focus on:
- Combination Therapies: Investigating combinations of tilvestamab with chemotherapy, as reducing fibrotic stroma could potentially improve chemotherapy penetration.
- Immunotherapy Combinations: Given the absence of observed immunogenicity, combinations with immunotherapy might be less promising.
- Patient Selection: Better selection of study populations, potentially focusing on patients with mesenchymal subtype PROCs, could be beneficial.
- Broader Indications: Exploring the efficacy of AXL inhibition with tilvestamab in other indications where AXL plays a significant role.
- Further Biomarker Studies: Continued investigation into biomarkers that predict response or resistance to AXL inhibition.
Summary updated